OSE Immunotherapeutics has teamed up with French start-up MAbSilico to use artificial intelligence-based solutions for therapeutic antibody drug development.
OSE Immunotherapeutics, a French biotech focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases, said it plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies.
MAbSilico solutions have already been tested and validated by OSE Immunotherapeutics and will be used for six antibody programs, including novel bispecific antibodies.
AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.
“Due to the devastating nature of these [immuno-oncology and autoimmune] diseases, our development strategies need to be accelerated and artificial intelligence solutions for drug discovery offered by MAbSilico can be a great asset to achieve this goal,” said Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics.
While all MAbSilico’s commercialised solutions are included in this three-year agreement, OSE Immunotherapeutics also gains early access to MAbSilico’s SaaS (Software as a Service) and technologies in development including those for the conception of therapeutic antibodies optimised for bioproduction.
OSE provides internal data to MAbSilico in order to feed their algorithms in development and deliver new technology faster.
Vincent Puard, CEO of MAbSilico, said: “This partnership demonstrates the need to fasten new AI-based solutions for antibody drug discovery. We believe that with the trust and collaboration of OSE, we will accelerate the release of our software and new technologies.”